The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

An FDA Advisory Committee has recommended that Pfizer be allowed to market Celebrex to children ages 2 and older who suffer from Juvenile Rheumatoid Arthritis (JRA). The panel voted 15-1 that the drug was an effective treatment and that its benefits outweighed its risks. The panel members split on the issue of safety, voting 8-7 (with one abstention) that available data does not demonstrate safety. The panel strongly recommends that the safety of Celebrex in children be monitored for 10-20 years, possibly by creating a registry of patients. Panel member Dr. Joan Bathon, rheumatologist at Johns Hopkins, said, “The feeling was short-term efficacy looked good and short-term safety was not an issue. Long-term safety is totally unknown and needs to be known.” The FDA is not required to take the advice of its expert panels, but it usually does.

Comments are closed.

Of Interest